BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25263685)

  • 1. PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy.
    Pan D; She W; Guo C; Luo K; Yi Q; Gu Z
    Biomaterials; 2014 Dec; 35(38):10080-92. PubMed ID: 25263685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy.
    She W; Luo K; Zhang C; Wang G; Geng Y; Li L; He B; Gu Z
    Biomaterials; 2013 Feb; 34(5):1613-23. PubMed ID: 23195490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
    Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
    Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
    Cabral H; Nishiyama N; Kataoka K
    J Control Release; 2007 Aug; 121(3):146-55. PubMed ID: 17628162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR; Gerberich JL; Nowotnik DP; Howell SB
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
    Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
    Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dye-cored polylysine dendrimer as luminescent nanoplatform for imaging-guided anticancer drug delivery.
    Zhu P; Younis MR; Ma G; Zhang Q; An R; Wang K; Dong J
    Colloids Surf B Biointerfaces; 2023 Feb; 222():113130. PubMed ID: 36623376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles.
    Cabral H; Nishiyama N; Okazaki S; Koyama H; Kataoka K
    J Control Release; 2005 Jan; 101(1-3):223-32. PubMed ID: 15588907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
    Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
    Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).
    Niidome T; Yamauchi H; Takahashi K; Naoyama K; Watanabe K; Mori T; Katayama Y
    J Biomater Sci Polym Ed; 2014; 25(13):1362-73. PubMed ID: 25040893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
    Yang J; Liu W; Sui M; Tang J; Shen Y
    Biomaterials; 2011 Dec; 32(34):9136-43. PubMed ID: 21889206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis.
    Rafi M; Cabral H; Kano MR; Mi P; Iwata C; Yashiro M; Hirakawa K; Miyazono K; Nishiyama N; Kataoka K
    J Control Release; 2012 Apr; 159(2):189-96. PubMed ID: 22326402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linear-Dendritic Polymer-Platinum Complexes Forming Well-Defined Nanocapsules for Acid-Responsive Drug Delivery.
    Liu K; Xiang J; Wang G; Xu H; Piao Y; Liu X; Tang J; Shen Y; Zhou Z
    ACS Appl Mater Interfaces; 2021 Sep; 13(37):44028-44040. PubMed ID: 34499483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW; van der Born K; Erkelens CA; Hamelers IH; Peters GJ; Boven E; de Kroon AI
    Anticancer Drugs; 2008 Aug; 19(7):721-7. PubMed ID: 18594214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting.
    Murakami M; Cabral H; Matsumoto Y; Wu S; Kano MR; Yamori T; Nishiyama N; Kataoka K
    Sci Transl Med; 2011 Jan; 3(64):64ra2. PubMed ID: 21209412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
    Hu FQ; Zhang YY; You J; Yuan H; Du YZ
    Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.